Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ammoxetine hydrochloride - CSPC Zhongqi Pharmaceutical Technology

Next Previous
Drug Profile

Ammoxetine hydrochloride - CSPC Zhongqi Pharmaceutical Technology

Alternative Names: Ammuxetine hydrochloride - CSPC ZhongQi Pharmaceutical Technology

Latest Information Update: 17 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Academy of Military Medical Sciences
  • Class Analgesics; Antidepressants; Anxiolytics; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 10 May 2026 CSPC ZhongQi Pharmaceutical Technology initiated a phase I pharmacokinetic trial in Healthy volunteers in China (PO, Tablet) (NCT07694869)
  • 30 Mar 2026 CSPC ZhongQi Pharmaceutical Technology initiates enrolment in a phase I Pharmacokinetic trial in China (PO)(NCT07694843)
  • 14 Feb 2025 CSPC ZhongQi Pharmaceutical Technology plans a phase III trial for Major Depressive Disorder (PO, Tablet) in February 2025 (NCT06827431)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top